SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/8/2186 |
| _version_ | 1797560129410826240 |
|---|---|
| author | Ishita Gupta Balsam Rizeq Eyad Elkord Semir Vranic Ala-Eddin Al Moustafa |
| author_facet | Ishita Gupta Balsam Rizeq Eyad Elkord Semir Vranic Ala-Eddin Al Moustafa |
| author_sort | Ishita Gupta |
| collection | DOAJ |
| description | Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of <i>ACE-2</i> and <i>TMPRSS2</i> genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer. |
| first_indexed | 2024-03-10T17:56:07Z |
| format | Article |
| id | doaj.art-8e415e16223c40df8ee78d97cd47faef |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T17:56:07Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8e415e16223c40df8ee78d97cd47faef2023-11-20T09:12:09ZengMDPI AGCancers2072-66942020-08-01128218610.3390/cancers12082186SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic ModalitiesIshita Gupta0Balsam Rizeq1Eyad Elkord2Semir Vranic3Ala-Eddin Al Moustafa4College of Medicine, QU Health, Qatar University, 2713 Doha, QatarCollege of Medicine, QU Health, Qatar University, 2713 Doha, QatarQatar Biomedical Research Institute & 4Hamad Bin Khalifa University, 34110 Doha, QatarCollege of Medicine, QU Health, Qatar University, 2713 Doha, QatarCollege of Medicine, QU Health, Qatar University, 2713 Doha, QatarHuman coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2), that promotes cellular entry of this virus in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2 coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein provide a comprehensive and up-to-date overview of the role of <i>ACE-2</i> and <i>TMPRSS2</i> genes, as key entry elements as well as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the applications and capacities of various remedial approaches for infected individuals, especially those with lung cancer.https://www.mdpi.com/2072-6694/12/8/2186COVID-19CoronavirusSARS-CoV-2lung cancerACE-2TMPRSS2 |
| spellingShingle | Ishita Gupta Balsam Rizeq Eyad Elkord Semir Vranic Ala-Eddin Al Moustafa SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities Cancers COVID-19 Coronavirus SARS-CoV-2 lung cancer ACE-2 TMPRSS2 |
| title | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_full | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_fullStr | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_full_unstemmed | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_short | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities |
| title_sort | sars cov 2 infection and lung cancer potential therapeutic modalities |
| topic | COVID-19 Coronavirus SARS-CoV-2 lung cancer ACE-2 TMPRSS2 |
| url | https://www.mdpi.com/2072-6694/12/8/2186 |
| work_keys_str_mv | AT ishitagupta sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT balsamrizeq sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT eyadelkord sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT semirvranic sarscov2infectionandlungcancerpotentialtherapeuticmodalities AT alaeddinalmoustafa sarscov2infectionandlungcancerpotentialtherapeuticmodalities |